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OBJECTIVES The rationale of this study was to identify risk factors that predict early thrombotic events and
angiographic restenosis after stenting in small coronary arteries.
BACKGROUND Rates of cardiac complications and restenosis after percutaneous coronary intervention are
higher in patients with small versus large coronary arteries. Because of discordant results,
randomized studies comparing stent placement with balloon angioplasty could not establish
the best interventional approach to use in this high-risk subset of patients. This study of
predictive factors, with special focus on stent design, may provide particular help in this
regard.
METHODS Clinical, lesion-related, and procedural data of a large and unselected population of 3,156
consecutive patients were analyzed in a logistic regression model for both early and late
complications. Repeat angiography at six months was performed in 80.8% of eligible patients.
RESULTS The strongest risk factors for early thrombotic events (cumulative incidence of 4.2%) were the
presence of an acute coronary syndrome and reduced left ventricular function. The stent
design had no influence on early thrombotic complications. Restenosis (overall rate of 38.4%)
was predominantly influenced by procedure-related variables, including the stent design and
stented segment length. The incidence of restenosis varied from 29.6% to 55.8%, depending
on the stent design used.
CONCLUSIONS Clinical factors known before the procedure are predominant risk factors for early thrombotic
complications, underscoring the need for potent antiplatelet regimens in these patients. In
contrast, our findings suggest a major impact of procedural factors, including the choice of
stent type, on restenosis. (J Am Coll Cardiol 2002;40:882–9) © 2002 by the American
College of Cardiology Foundation
Percutaneous interventions in small coronary vessels (3.0
mm) constitute a considerable proportion (30% to 50%) of
the one million coronary catheter-based procedures per-
formed worldwide each year. Percutaneous transluminal
coronary angioplasty (PTCA) and stent placement are the
two most frequently used interventions in patients with
coronary artery disease (1). Large coronary vessels represent
an established indication for stenting, which is superior to
PTCA, as shown in several randomized clinical trials (2,3).
The role of systematic stent placement in small coronary
arteries remains less well defined, with two randomized
studies showing a significant reduction in angiographic
restenosis rates (4,5), which could not be confirmed by two
other comparable randomized studies (6,7). The factors
responsible for this discrepancy are not known.
Several studies have assessed the predictive factors for
major adverse cardiac events within the first 30 days, as well
as for angiographic restenosis at six months after stent
placement (8–11), but these findings may not be applicable
to small coronary arteries owing to stent placement in large
coronary arteries in the majority of patients. Furthermore, in
most of the studies, the Palmaz-Schatz stent was the only
type of stent used, and the impact of different stent designs
on early and late outcomes in small coronary arteries is not
known. A number of randomized trials have been under-
taken to compare various stent models (12–15). Random-
ized trials often excluded patients with small coronary
arteries and complex lesion morphologies. Therefore, their
results may not be extrapolated to small coronary arteries.
Studies focusing on this category of patients may help to
explain the differences in the randomized stenting versus
PTCA trials, resulting in a further refinement of the
interventional approach.
In the present study, we analyzed the specific value of
clinical, lesion-related, and procedural variables in predict-
ing the risk of early thrombotic events and angiographic
restenosis after stenting in a consecutive series of patients
treated with various coronary stent designs in small coronary
arteries.
METHODS
Patients. During a period of five years, coronary stent
placement was performed in a consecutive series of 5,881
patients with symptomatic coronary artery disease. The
population of the current study consisted of 3,156 patients
with a reference vessel size3.0 mm. Patients with unstable
angina or acute myocardial infarction (MI) were included in
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this analysis. All patients were asked to undergo repeat
angiography at six months, or earlier in the case of symp-
toms or objective signs of myocardial ischemia, as well as a
clinical follow-up at 6 and 12 months. The protocol of
routine clinical and angiographic follow-up studies has been
approved by our institutional Ethics Committee.
Stent placement and post-stenting treatment. During
the intervention, patients received heparin and aspirin
intravenously. In addition, 37.7% of patients considered at
higher risk of stent thrombosis (acute MI, persistent throm-
bus at the stent site, large residual dissections) also received
a glycoprotein IIb/IIIa inhibitor (e.g., a bolus and 12-h
infusion regimen of abciximab). Post-procedural therapy
consisted in 250 mg ticlopidine plus 100 mg aspirin twice
daily for four weeks; aspirin was taken indefinitely.
Stents of various designs were inserted using either
hand-crimped stents on conventional angioplasty balloons
or the provided stent-delivery systems. The characteristics
described subsequently for each stent type inserted in 100
patients in this series are those reported by the manufac-
turer. Most stent types had the slotted-tube design, includ-
ing the classic Palmaz-Schatz stent (Johnson & Johnson
Interventional Systems, Warren, New Jersey), the JO-Stent
(JOMED International AB, Helsingborg, Sweden), and the
Inflow stainless-steel stent (ID-Steel; Inflow Dynamics,
Munich, Germany). The Inflow gold-plated stent (ID-
Gold, Inflow Dynamics) is a stent with the same design as
the ID-Steel stent, but it is plated with 0.005 mm of gold.
The Pura-A stent (Devon Medical, Hamburg, Germany)
has a slotted-tube design with longitudinal Y connections.
The Multi-Link stent (Guidant, Advanced Cardiovascular
Systems, Santa Clara, California) is made of a 0.050-mm
stainless-steel wire that forms multiple rings connected with
multiple links. The Multi-Link Duet stent (Guidant) also
has an interconnected ring design, but the strut thickness is
0.140 mm. The NIR stent (Scimed, Boston Scientific
Europe, Verviers, Belgium) has a continuous, uniform,
multicellular design. Other stent types included the ACT-
One and Paragon stents (Progressive Angioplasty Systems,
Menlo Park, California), AVE GFX and Wiktor stents
(Medtronic, Minneapolis, Minnesota), Crossflex and
Crown stents (Johnson & Johnson Interventional Systems,
Warren, New Jersey), Freedom stents (Global Therapeutics
Inc., Broomfield, Colorado), ID Flex stents (Inflow Dy-
namics, Munich, Germany), Jomed graft stents (JOMED
International AB, Helsingborg, Sweden), MAC and
Omega stents (AMG, Raesfeld-Erle, Germany); all these
stent types together were inserted in a total number of 118
patients.
Angiographic evaluation. Lesions were classified accord-
ing to the modified American College of Cardiology/
American Heart Association grading system (types A, B1,
B2, and C). An automated edge-detection system (CMS
version 4.0, Medis Medical Imaging Systems, Nuenen, The
Netherlands) was used for off-line analysis of the digital
angiograms. Matched views were selected for angiograms
recorded before and immediately after the intervention and
at follow-up. The variables obtained were lesion length,
vessel size, minimal lumen diameter, diameter stenosis, and
diameter of the maximally inflated balloon during stent
placement. Late lumen loss was calculated as the difference
in minimal lumen diameter measurements between after the
procedure and at follow-up.
Definitions. Procedural success was defined as stent place-
ment at the desired site, with a satisfactory angiographic
result (i.e., final residual stenosis 30%) and Thombolysis
in Myocardial Infarction distal flow grade 2. Residual
dissections at the end of the procedure were defined as
5-mm-long dissections (8). An ejection fraction 50%
was considered as reduced left ventricular (LV) function.
The cumulative early thrombotic event rate was defined as
death, nonfatal MI or documented stent occlusion, as
demonstrated by angiography, occurring within the first 30
days after stent placement. The diagnosis of MI was based
on typical chest pain combined with either new pathologic
Q waves or a rise in creatine kinase2 times the upper limit
of normal (160 U/l), with a concomitant increase in the
MB isoenzyme. Target lesion revascularization (TLR) was
performed in the presence of angiographic restenosis and
typical chest pain or objective signs of myocardial ischemia.
Patients with successful stent placement and without a
major adverse cardiac event, including death, nonfatal MI,
documented stent occlusion, or TLR within the first 30 days
after stenting, were considered eligible for angiographic
follow-up. Restenosis was defined as diameter stenosis
50% at follow-up angiography.
Statistical analysis. Results are expressed as the mean
value  SD or as proportions (%). Analysis of early clinical
outcomes was performed on the entire patient population
(n 3,156), whereas analysis of late angiographic outcomes
was done on patients eligible for repeat angiography. All
variables were entered into a multivariate logistic regression
model to test for their independent effects. Analysis of early
thrombotic events was made per patient, whereas analysis of
restenosis was lesion-based. To eliminate a potential clus-
tering effect in patients with a multilesion intervention (16),
bootstrapping with 1,000 replications was applied for the
calculation of regression coefficients, odds ratios, and 95%
confidence intervals for each co-variate in the model, as well
as for model calibration and validation (17). To control the
significance level when comparing different stent types
(control for multiple comparisons), a closed-testing proce-
dure was applied (18). In a step-down manner, it started
Abbreviations and Acronyms
LV  left ventricular
MI  myocardial infarction
PTCA  percutaneous transluminal coronary angioplasty
TLR  target lesion revascularization
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with a test of the global null hypothesis at a full alpha level.
In case of rejection, it proceeded with all null hypotheses on
a lower stage, thus eliminating one group. If a null hypoth-
esis could not be rejected, all hypotheses containing it were
also rejected. With this test procedure, the significance
alpha level can be controlled (18). Statistical significance
was defined as p  0.05.
RESULTS
The analyzed variables were grouped into three categories:
clinical, lesion-related, and procedural. In Tables 1 and 2,
these variables are summarized for all patients.
Early clinical outcomes. The cumulative thrombotic event
rate was 4.2% (n  133). This included, in the order of
severity, 85 deaths (2.7%), 29 patients with nonfatal MI
(0.9%), and 19 patients with angiographically documented
stent occlusion (0.6%).
Multivariate analysis for early thrombotic events. Figure
1 depicts eight clinical, lesion-related, and procedure-
related variables that were identified as independent risk
factors for the occurrence of thrombotic events. The stron-
gest independent predictors were the clinical variables: the
presence of an acute coronary syndrome and reduced LV
function (Table 3). Among the procedure-related variables,
the presence of a residual dissection at the end of the
intervention was a strong predictor of thrombotic events.
Female patients, as well as patients with complex, de novo,
or long stented lesions, also had an increased risk of a major
early adverse event. The stent design had no significant
influence on early thrombotic events (p  0.38).
Late angiographic outcome. Of the 3,156 study patients,
206 patients were not eligible for follow-up angiography
because of an early thrombotic event (n  133), unsuccess-
ful stent placement (n  32) and TLR within 30 days after
stent placement (n 41). Repeat angiography at six months
was carried out in 2,385 (80.8%) of 2,950 eligible patients.
A total of 2,978 lesions of 2,385 patients (1.17 lesions/
patient) were included for the six-month outcome analysis.
The criterion for angiographic restenosis was reached in 916
(38.4%) of 2,385 patients. The TLR rate at one year was
20.7% (652 of 3,156 patients).
Multivariate analysis for angiographic restenosis. Figure
2A presents nine clinical, lesion-related, and procedure-
related variables as independent risk factors for restenosis.
The stent design had the strongest independent influence
among the procedural variables (Table 4). Additional pre-
dictive factors included, in the order of significance, vessel
size, stented segment length, lesion complexity, stenosis
severity before the intervention, gender, balloon-to-vessel
ratio, diabetes mellitus, and lesion length.
Table 5 presents detailed information on baseline lesion
characteristics and average late lumen loss, as well as
restenosis and TLR rates, for the various stent designs.
There were no significant differences in vessel size between
the stent designs ranging from 2.57  0.30 mm for the
Pura-A stent to 2.63  0.31 mm for the Duet stent (p 
0.18). Lesion and stented segment length were significantly
different between the stent types, with the highest values in
the Multi-Link stent group (p  0.001 for both variables).
Table 1. Baseline Clinical Characteristics of Patient Population
(n  3,156)
Variable
Age (yrs) 64.7  11.2
Women 25.4%
Cardiovascular risk factors
Systemic hypertension 71.3%
Diabetes mellitus 22.8%
Cigarette smoking 40.1%
Hypercholesterolemia 240 mg/dl 56.0%
Acute coronary syndromes 44.9%
Previous MI 33.6%
Previous CABG 9.7%
No. of narrowed coronary arteries
One 25.8%
Two 33.3%
Three 40.9%
Reduced LV function 26.2%
Data are presented as the mean value  SD or percentage of patients.
CABG  coronary artery bypass graft surgery; LV  left ventricular; MI 
myocardial infarction.
Table 2. Coronary Artery Narrowed and Procedure-Related
Characteristics of Patient Population (n  3,156)
Lesion-related variables
Vessel
LMCA 0.6%
LAD 48.6%
LCx 26.4%
RCA 21.7%
Bypass graft 2.7%
Lesion type
A 5.0%
B1 20.0%
B2 50.9%
C 24.1%
Chronic occlusions 13.0%
Restenotic lesions 17.3%
Lesion length (mm) 12.0  7.0
Vessel size (mm) 2.59  0.28
Diameter stenosis before procedure (%) 76.6  16.6
Procedural variables
Maximal balloon pressure (atm) 13.5  3.0
Balloon-to-vessel ratio 1.13  0.13
Length of stented segment (mm) 19.4  11.8
Stent type
Devon Pura-A 8.3%
Inflow gold 9.7%
Inflow steel 14.5%
JO-Stent 13.8%
Multi-Link classic 17.1%
Duet 9.8%
NIR 6.3%
Palmaz-Schatz 15.4%
Others 5.1%
Diameter stenosis after procedure (%) 4.3  9.6
Periprocedural abciximab administration 37.7%
Data are presented as the percentage of patients or mean value  SD.
LAD  left anterior descending coronary artery; LCx  left circumflex coronary
artery; LMCA  left main coronary artery; RCA  right coronary artery.
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At follow-up, there were significant differences in angio-
graphic and clinical variables for restenosis between the
stent designs. Compared with the Palmaz-Schatz stent, the
Multi-Link stent resulted in 9.4% less late loss, a 19.6%
lower restenosis rate, and a 10.2% lower rate of TLR. In
contrast, use of the gold-plated Inflow stent resulted in a
28.2% increase in late loss, a 51.5% increase in the restenosis
rate, and a 48.9% increase in the TLR rate. Figure 2B
summarizes the results of the multivariate model with
respect to stent design in terms of the adjusted risk of
restenosis. Using the classic Palmaz-Schatz stent as a
reference, placement of the Multi-Link stent was associated
with the lowest risk of restenosis. With the JO-Stent, the
risk of restenosis was lower than that with the Palmaz-
Schatz stent; however, this did not reach statistical signifi-
cance. It is also evident that most of the stents in this series
(Duet, Palmaz-Schatz, Pura-A, ID-Steel, NIR) are not
significantly different from each other in terms of risk, as
shown in Figure 2B. However, the use of the ID-Gold stent
was associated with a significantly higher risk of restenosis
(odds ratio 1.81, confidence interval 1.30 to 2.51).
Impact of clinical, lesion-related, and procedural vari-
ables on outcome. This analysis is based on three catego-
ries of factors: 1) clinical variables; 2) lesion-related vari-
ables; and 3) procedural-related variables (Tables 1 and 2).
To assess each category’s contribution to the strength of the
final logistic regression models for early and late outcomes,
we analyzed partial models with variables from the respec-
tive categories by using the chi-square value (Fig. 3) as an
indicator of the predictive strength of the model. There is a
striking difference between the two analyses: although
clinical variables, including the presence of an acute coro-
nary syndrome and reduced LV function, are the primary
determinants of early thrombotic events, the importance of
these factors for angiographic restenosis is diminished. The
risk of restenosis is primarily determined by procedure-
related factors, including the stent design and length of the
stented segment. The importance of lesion-related factors,
including vessel size and lesion complexity, is subordinated
in this patient cohort, whereas the relevance of clinical
variables, with regard to restenosis, is small.
DISCUSSION
This is the first study to analyze the predictive factors for
short- and long-term outcomes in a large cohort of un-
selected patients who underwent stent placement in coro-
nary arteries with diameters 3.0 mm. Focusing on early
outcomes, the study identified two major baseline clinical
Figure 1. Significant and independent factors for thrombotic events occurring within the first 30 days, as derived from the multivariate model, displayed
with their relative risk and 95% confidence interval. The confidence interval for the continuous variable “stented segment length” was calculated for the first
versus third quartile: 10 vs. 25 mm. LV  left ventricular.
Table 3. Significant Independent Predictors of Thrombotic
Events Within 30 Days After Stent Placement, Identified by
Logistic Regression Analysis
Chi-Square
Statistic*
p
Value
Adjusted Odds
Ratio (95% CI)
Clinical variables
Female gender 6.5 0.011 1.64 (1.12–2.38)
Reduced LV function 38.4  0.001 3.08 (2.16–4.40)
Acute coronary syndrome 22.6  0.001 2.53 (1.73–3.72)
No hypertension 13.2  0.001 1.92 (1.35–2.70)
Lesion-related variables
Complex lesions (type B2/C) 6.9 0.009 2.09 (1.21–3.63)
Primary lesion 8.4 0.005 2.86 (1.41–5.89)
Procedural variables
Stented segment length† 7.6 0.006 1.21 (1.06–1.39)
Residual dissection 29.2  0.001 5.38 (2.92–9.92)
*Derived from the logistic regression model for thrombotic events. †The median value
was used as a cut-off point to define the two subgroups with the characteristic present
or absent, and the values defining the 25th and 75th percentiles were used to calculate
the respective odds ratios.
CI  confidence interval; LV  left ventricular.
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factors that were strong predictors of the occurrence of early
thrombotic events: the presence of an acute coronary syn-
drome and reduced LV function. With respect to angio-
graphically determined long-term outcomes, the study re-
vealed two major findings: 1) procedural and lesion-related
variables, but not baseline clinical factors, are the primary
determinants of the risk of restenosis; and 2) the stent
design is the strongest predictor of restenosis.
Although stent placement was initially approved by the
U.S. Food and Drug Administration for use only in large
coronary arteries (i.e., 3.0 mm), patients with smaller
arteries constitute a large group of those treated with
percutaneous coronary interventions in daily practice. Con-
sequently, the outcome of patients with elective stent
placement in small coronary arteries has been compared
with the outcome of those treated with balloon angioplasty
in several recent randomized trials (4–7). As only two of
four studies have shown a significant long-term benefit of
routine stent placement (4,5), the advantage of a strategy of
routine stent placement in small coronary arteries remains to
be better studied. In the present study, we provide a
comprehensive analysis of the risk of early thrombotic
events after stenting and angiographic restenosis in a large
population that had stent placement in small coronary
arteries, including many patients with acute coronary syn-
dromes who had been excluded from most previous trials.
Predictors of early thrombotic events. In this analysis, a
large number of factors were included: baseline clinical and
lesion-related characteristics available before the interven-
tion, as well as procedural factors describing the intervention
and the final results. Eight factors were identified as
significant and independent predictors of the occurrence of
early thrombotic events. The most significant factors were
two variables available before the intervention: the presence
of an acute coronary syndrome and reduced LV function. In
addition, the presence of a postprocedural dissection con-
tributed significantly to the risk of thrombotic events. Our
analysis of risk is in keeping with the results from previous
analyses of larger vessels (8,9). These studies identified the
influence of the aforementioned clinical variables, along
with procedural factors, including lesion complexity and
length of the stented segment, as risk factors for the
occurrence of early stent thrombosis. The importance of
Figure 2. (A) Significant and independent factors for angiographic restenosis at six months, as derived from the multivariate model, displayed with their
relative risk and 95% confidence interval. For continuous variables, these were calculated for the first versus third quartile (lesion length: 7.4 vs. 15.3 mm;
small vessel size: 2.25 vs. 2.94 mm; stenosis severity before the intervention: 65.7% vs. 89.9%; balloon/vessel ratio: 1.02 vs. 1.14; and stented segment length:
15 vs. 25 mm). (B) Adjusted risk (with odds ratio and 95% confidence interval) for restenosis associated with each stent type, as derived from the multivariate
model. The risk was calculated using the Palmaz-Schatz stent as a reference.
Table 4. Significant Independent Predictors of Restenosis
Identified by Logistic Regression Analysis
Chi-Square
Statistic*
p
Value
Adjusted Odds
Ratio (95% CI)
Clinical variables
Female gender 9.2 0.0024 0.73 (0.60–0.90)
Diabetes 6.5 0.0108 1.29 (1.06–1.57)
Lesion-related variables
Complex lesions
(type B2/C)
14.1 0.0002 1.46 (1.20–1.77)
Lesion length† 4.5 0.0337 1.12 (1.01–1.24)
Vessel size† 47.2  0.0001 1.59 (1.36–1.82)
Diameter stenosis before
intervention†
10.7 0.0011 1.29 (1.11–1.50)
Procedural variables
Stented segment length† 29.3  0.0001 1.31 (1.19–1.45)
Balloon/vessel ratio 9.1 0.0026 0.86 (0.77–0.95)
Stent type‡ 47.3  0.0001
Multi-Link 0.56 (0.40–0.77)
JO-Stent 0.73 (0.53–1.01)
Duet 0.95 (0.66–1.35)
Palmaz-Schatz 1
ID-steel 1.02 (0.76–1.36)
Pura-A 1.10 (0.79–1.53)
NIR 1.18 (0.83–1.69)
ID-Gold 1.81 (1.30–2.51)
*Derived from the logistic regression model for restenosis. †For these continuous
variables, the median value was used as a cut-off point to define the two subgroups
with the characteristic present or absent, and the values defining the 25th and 75th
percentiles were used to calculate the respective odds ratios. ‡The odds ratios for the
different stent types were calculated using the Palmaz-Schatz stent as a reference.
CI  confidence interval.
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clinical risk factors identifiable before the interventional
procedure indicates a need for individual risk stratification
and a refined interventional approach (e.g., with an inten-
sified antithrombotic regimen with potent glycoprotein
IIb/IIIa inhibitors in a high-risk subset of patients).
Although it has been demonstrated that a coiled stent
design may have a significant impact on the incidence of
subacute stent thrombosis within the first month after
stenting (13), our analysis did not identify the use of various
noncoiled stent designs as an independent predictor of
thrombotic events in this patient cohort with small coronary
arteries.
Predictors of restenosis. The predictive model for binary
restenosis identified nine independent factors: female gen-
der, diabetes mellitus, lesion complexity, long lesions, small
vessel size, stenosis severity before the intervention, high
balloon/vessel ratio, long stented segment, and stent design
(Fig. 2A). Small vessel size, which was the second strongest
risk factor in the current analysis, is a well-known potent
predictor of restenosis after PTCA, as well as after stent
placement (19–22). Elezi et al. (20) demonstrated that the
risk of restenosis after stent placement may vary from 29.6%
to 53.5% in patients with small coronary arteries (i.e.,
diameter 2.8 mm), depending on the presence of addi-
tional risk factors, such as complex lesion morphology and
diabetes mellitus.
Most of the other identified predictors of restenosis are in
keeping with earlier reports. However, the results of the
earlier studies were confined to the sole use of the Palmaz-
Schatz stent, and the influence of stent design has not been
incorporated into the previous statistical models. In this
series of patients with small coronary arteries, we used eight
different stent designs of various slotted-tube and intercon-
nected ring designs. In the current analysis, stent design was
identified as a strong independent predictor of angiographic
restenosis. This influence of stent design was also apparent
in the analysis of angiographic late lumen loss and the need
of TLR. The results are in agreement with four recent
randomized clinical trials demonstrating that stent design
(12,13), stent coating (23) and stent strut thickness (24) may
determine restenosis-free survival. In most of these studies,
patients with small coronary arteries and complex lesion
morphologies were included. In contrast, several other
randomized trials that excluded patients with small coronary
arteries or complex lesion morphologies have failed to detect
differences between different stent designs (14,15). There-
fore, the results of our analysis suggest that the exclusion of
patients with small coronary arteries may have masked
differences among the tested stent designs in some previous
trials.
When comparing elective stent placement with conven-
tional PTCA in patients with small coronary arteries, two of
four randomized trials have shown a significantly reduced
restenosis rate after placement of a dedicated small vessel
stent—the BeStent Small (Medtronic, Minneapolis, Min-
nesota) (4,5). Dedicated stents for small arteries have fewerTa
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struts, cells, or loops per circumference, compared with
large-vessel stents, and/or they have thinner stent struts to
reduce the metal coverage and load relative to the circum-
ference of the vessel wall. The Intracoronary Stenting or
Angioplasty for Restenosis Reduction in Small Arteries
Trial (ISAR-SMART), in which the Multi-Link stent was
used, demonstrated an almost identical clinical and angio-
graphic long-term outcome in patients randomized to either
treatment regimen (6). Although the current study supports
the hypothesis that a potential cause for the divergent trial
results could be the use of different stent designs, our study
also demonstrates that the design of the nondedicated
Multi-Link stent is associated with the lowest restenosis
rate in small coronary arteries, compared with the other
stent designs used in this study. Therefore, it is unlikely that
the differences in stent design between the BeStent Small
and Multi-Link stent are the sole cause for the divergent
trial results. Recently, we demonstrated a strong relation-
ship between the residual stenosis grade after PTCA and
restenosis reduction after stenting in a meta-analysis of stent
versus PTCA trials in small coronary arteries (25). Conse-
quently, the residual stenosis grade achieved with PTCA
has also been considered as a plausible explanation for the
divergent trial results. Finally, relevant differences in patient
and lesion characteristics, including lesion complexity and
stented segment length, may also provide an additional
explanation for the discrepancy of the study results.
Study limitations. Although all data were prospectively
collected with the objective of assessing the short- and
long-term outcomes after stenting, the analysis was per-
formed retrospectively. Of note, our main outcome mea-
sure—angiographic restenosis—was based on quantitative
angiographic evaluations by operators blinded to the actual
stent type used. However, additional randomized trials are
required to establish the definite role of the stent type in
restenosis development after stenting of small coronary
arteries.
An additional limitation of the study is the absence of the
BeStent Small, which has been used in three randomized
trials comparing stenting with PTCA in small coronary
arteries (4,5,7). Finally, we acknowledge the limitation
related to the availability of follow-up angiographic studies
in 80.8% of patients. Previous trials of restenosis have also
shown the impossibility of achieving higher rates because of
patient refusal in an inevitable proportion of cases.
Conclusions. Early thrombotic complications occurred in
a low percentage of patients in this large, unselected
population of 3,156 patients with stent placement in small
coronary arteries. The predictors of early complications are
predominantly clinical factors, including the presence of an
acute coronary syndrome and reduced LV function, indi-
cating the need for pre-interventional risk stratification,
with an intensified antithrombotic regimen for high-risk
patients. The development of angiographic restenosis is
primarily influenced by procedural variables, particularly
stent design. Therefore, judicious selection of stent designs
is required before stenting of small coronary arteries.
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